摘要:
A method of manufacturing a plugged honeycomb structure has a plugging process which includes the steps of: immersing one end (a first end) of a honeycomb base material in a plugging slurry while vibrating the plugging slurry; after bringing an internal part of a cell into a negative pressure and then returning it into an atmospheric pressure, vibrating the plugging slurry to make the plugging slurry enter a first open end of the cell; and drying the plugging slurry having entered the first open end of the cell to form a first plugging portion at the first end.
摘要:
A method is provided for manufacturing a plugged honeycomb structure 30 including a honeycomb substrate 1 and plugging portions 15 arranged so as to form complementary checkered patterns at both end surfaces 11 and 21 of the honeycomb substrate 1. The method includes attaching a first mask film 4a to the first end surface 11 of the honeycomb substrate 1, making slurry permeation holes 3a to introduce a plugging slurry 6, attaching a second mask film 4b to the second end surface 21 of the honeycomb substrate 1, making slurry permeation holes 3b, allowing air to flow into the cells 2 so as to discharge air giving a pressure of 0.05 to 5 MPa between the first mask film 4a and the honeycomb substrate 1; and filling cell opening end portions 7 with the plugging slurry 6 to fire the resultant slurry filled substrate 20.
摘要:
The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.
摘要:
The present invention relates to a compound represented by formula (I): wherein R1 represents a C1-3 alkyl group, R2 represents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.
摘要:
The present invention relates to a process for preparing a compound of formula (6a): wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents shown below; Ar2 represents a pyridinyl group, a pyrimidinyl group or a phenyl group which may be substituted with 1 to 3 substituents; and R11 represents a group selected from certain substituents.
摘要翻译:本发明涉及式(6a)化合物的制备方法:其中Ar 1表示可被1〜3个取代基取代的咪唑基, Ar 2表示吡啶基,嘧啶基或可被1〜3个取代基取代的苯基; R 11表示选自某些取代基的基团。
摘要:
The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. In the formula, Q indicates NH, O or S; and R1, R2, R3, R4 and R5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C1-6 alkyl group or a group represented by the formula —X-A (wherein X indicates a single bond, an optionally substituted C1-6 alkylene group etc.; and A indicates an optionally substituted C6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).
摘要:
The present invention provides a most suitable prodrug of a cinnamide compound. The prodrug is represented by Formula (I) wherein Ra and Rb each denote a C1-6 alkyl group or the like; Xa denotes a methoxy group or a fluorine atom; Y denotes a phosphono group or the like; and A denotes a cyclic lactam derivative.
摘要:
A crystal of 1-[1-[2-(7-methoxy-2,2-dimethyl-4-oxochroman-8-yl)-ethyl]piperidin-4-yl]-N-methyl-1H-indole-6-carboxamide fumarate which has peaks at chemical shifts of about 124.0 ppm and about 26.8 ppm in a 13C solid NMR spectrum.
摘要:
The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R1 and R2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R3 represents a hydrogen atom or the like; and R6 represents a hydrogen atom or the like. This compound has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor, and is useful as an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage.
摘要翻译:本发明涉及由下式表示的化合物,其药理学上可接受的盐或其作为药物的用途:其中R 1和R 2是相邻的取代基 并且与它们各自连接的两个碳原子一起形成5-至7-元非芳族碳环基等,其可以被1至4个选自以下的取代基取代:(1)氧代 基团,(2)羟基等; R 3表示氢原子等; R 6表示氢原子等。 该化合物与5-HT 1A受体的结合强度优异,对受体具有拮抗作用,可用作治疗或预防下尿路症状的药剂,特别是有关尿液储存的症状。
摘要:
A vacuum cleaner has a suction air inlet disposed in front of an electric blower and a dust chamber detachably installed to the rear of the electric blower. The vacuum cleaner further embodies a swivel caster and wheels for facilitating transportability thereof, wherein the swivel caster is provided in front of the electric blower. By not having the dust chamber above the swivel caster, regardless of the amount of dust accumulated in the dust chamber, the load that is distributed on the swivel caster stays substantially unchanged, thereby enhancing durability of the swivel caster. Furthermore, in such configuration loading and unloading of the dust chamber can be carried out without being interfered with a hose due to the placement of the suction air outlet connected with the hose and the dust chamber on opposite ends of the vacuum cleaner.